0001213900-18-010349.txt : 20180807 0001213900-18-010349.hdr.sgml : 20180807 20180807141806 ACCESSION NUMBER: 0001213900-18-010349 CONFORMED SUBMISSION TYPE: DEFA14C PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180807 DATE AS OF CHANGE: 20180807 EFFECTIVENESS DATE: 20180807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Yew Bio-Pharm Group, Inc. CENTRAL INDEX KEY: 0001548240 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] IRS NUMBER: 261579105 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14C SEC ACT: 1934 Act SEC FILE NUMBER: 000-54701 FILM NUMBER: 18997387 BUSINESS ADDRESS: STREET 1: 9460 TELSTAR AVENUE, SUITE 6 CITY: EL MONTE STATE: CA ZIP: 91731 BUSINESS PHONE: 626-401-9588 MAIL ADDRESS: STREET 1: 9460 TELSTAR AVENUE, SUITE 6 CITY: EL MONTE STATE: CA ZIP: 91731 DEFA14C 1 defa14c0818_yewbiopharm.htm DEFINITIVE ADDITIONAL INFORMATION STATEMENT
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 14C INFORMATION

 

Information Statement Pursuant to Section 14(c)

of the Securities Exchange Act of 1934

 

Check the appropriate box:

 

☐ Preliminary Information Statement
   
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
   
☐ Definitive Information Statement
   
☒ Definitive Additional Materials  

 

YEW BIO-PHARM GROUP, INC.

(Name of Registrant as Specified In Its Charter)

 

Payment of Filing Fee (Check the appropriate box):

 

☒ No fee required.
   
☐ Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

 

  1) Title of each class of securities to which transaction applies:

 

  2) Aggregate number of securities to which transaction applies:

 

  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

 

  4) Proposed maximum aggregate value of transaction:

 

  5) Total fee paid:

 

☐ Fee paid previously with preliminary materials.
   
☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

  1) Amount Previously Paid:

 

  2) Form, Schedule or Registration Statement No.:

 

  3) Filing Party:

 

  4) Date Filed:

 

 

 

 

 

YEW BIO-PHARM GROUP, INC.
9460 Telstar Avenue, Suite 6

El Monte, California 91731

NOTICE OF INTERNET AVAILABILITY OF INFORMATION STATEMENT MATERIALS

To Our Stockholders:

An Information Statement is being made available by the Board of Directors of Yew Bio-Pharm Group, Inc., a Nevada corporation (the “Company”), to holders of record of the Company’s common stock at the close of business on July 27, 2018 (the “Record Date”). The purpose of this Information Statement is to inform the Company stockholders of the following action taken by written consent of the holders of a majority of the Company’s voting stock, dated July 27, 2018:

 

“Approval to grant the Board of Directors discretionary authority to amend the Company's Articles of Incorporation to affect a reverse stock split of the issued and outstanding shares of our Common Stock, par value $0.001 per share, such split to combine a whole number of outstanding shares of our Common Stock in a range of not less than six (6) shares and not more than ten (10) shares, into one share of Common Stock at any time prior to June 30, 2019 (the “Reverse Split Proposal”).”

 

The foregoing action was approved on July 27, 2018 by our Board of Directors. In addition, on July 27, 2018 the holders of 51.71% of the Company’s outstanding voting securities, as of the Record Date approved the foregoing action. The number of shares voting for the proposals was sufficient for approval.

 

Section 78.320 of the Nevada Revised Statutes (the “NRS”) provides in part that any action required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent thereto is signed by stockholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action at a meeting, then that proportion of written consents is required.

Important Notice Regarding the Availability of Information Statement Materials

Pursuant to Securities and Exchange Commission Rule §240.14C-2, you are receiving this notice that the Information Statement is available on the Internet. This communication provides only a brief overview of the more complete Information Statement Materials. We encourage you to access and review all of the important information contained in the Information Statement Materials.

Follow the instructions below to view the materials or request printed or email copies.

Our Information Statement is available at www.yewbiopharm.com/investors/2018-meeting/.

If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a paper or e-mail copy. Please make your request for a copy by one of the following methods on or before August 17, 2018 to facilitate timely delivery.

 

-   E-mail to hpang@yewbiopharm.com
-   Mail at Yew Bio-Pharm Group, Inc., 9460 Telstar Avenue, Suite 6, El Monte, CA 91731
-   Telephone call to (626) 401-9588.

WE ARE NOT ASKING FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

 

By Order of the Board of Directors,
 
/s/ Zhiguo Wang
Zhiguo Wang, Chief Executive Officer
Dated: August 7, 2018